Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Gulf countries roll out more autonomous taxis - 2Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
- 3The top astronomical discoveries of 2025
- 4Three killed as unfinished building collapses on church service in Ghana
- 5Bondi Beach survivor criticizes police for inaction during terror attack
- Australian State Triggers Emergency Powers Amid Fuel Crisis
- 5 Critical Rules For Business Regulation Chiefs
- Living in the dark: Gaza’s struggle for electricity
- The new queen of country music has no scandals and no gimmicks — and just broke a record set by Taylor Swift
- Los Angeles County sees significant uptick in norovirus cases, officials say
- Clocks to go forward one hour in Europe as summer time starts
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- Best Amusement Park Bite: What Do You Very much want to Crunch On?
- Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
